1 Infliximab and Biosimilar Market Overview 1.1 Product Overview and Scope of Infliximab and Biosimilar 1.2 Infliximab and Biosimilar Segment by Type 1.2.1 Global Infliximab and Biosimilar Sales Growth Rate Comparison by Type (2021-2027) 1.2.2 Infliximab 1.2.3 Infliximab-dyyb 1.2.4 Infliximab-abda 1.3 Infliximab and Biosimilar Segment by Application 1.3.1 Global Infliximab and Biosimilar Sales Comparison by Application: (2021-2027) 1.3.2 Crohn's Disease 1.3.3 Pediatric Crohn's Disease 1.3.4 Ulcerative Colitis 1.3.5 Rheumatoid Arthritis 1.3.6 Ankylosing Spondylitis 1.3.7 Psoriatic Arthritis 1.3.8 Plaque Psoriasis 1.4 Global Infliximab and Biosimilar Market Size Estimates and Forecasts 1.4.1 Global Infliximab and Biosimilar Revenue 2016-2027 1.4.2 Global Infliximab and Biosimilar Sales 2016-2027 1.4.3 Infliximab and Biosimilar Market Size by Region: 2016 Versus 2021 Versus 2027 2 Infliximab and Biosimilar Market Competition by Manufacturers 2.1 Global Infliximab and Biosimilar Sales Market Share by Manufacturers (2016-2021) 2.2 Global Infliximab and Biosimilar Revenue Market Share by Manufacturers (2016-2021) 2.3 Global Infliximab and Biosimilar Average Price by Manufacturers (2016-2021) 2.4 Manufacturers Infliximab and Biosimilar Manufacturing Sites, Area Served, Product Type 2.5 Infliximab and Biosimilar Market Competitive Situation and Trends 2.5.1 Infliximab and Biosimilar Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Infliximab and Biosimilar Players Market Share by Revenue 2.5.3 Global Infliximab and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Infliximab and Biosimilar Retrospective Market Scenario by Region 3.1 Global Infliximab and Biosimilar Retrospective Market Scenario in Sales by Region: 2016-2021 3.2 Global Infliximab and Biosimilar Retrospective Market Scenario in Revenue by Region: 2016-2021 3.3 North America Infliximab and Biosimilar Market Facts & Figures by Country 3.3.1 North America Infliximab and Biosimilar Sales by Country 3.3.2 North America Infliximab and Biosimilar Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Infliximab and Biosimilar Market Facts & Figures by Country 3.4.1 Europe Infliximab and Biosimilar Sales by Country 3.4.2 Europe Infliximab and Biosimilar Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Infliximab and Biosimilar Market Facts & Figures by Region 3.5.1 Asia Pacific Infliximab and Biosimilar Sales by Region 3.5.2 Asia Pacific Infliximab and Biosimilar Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Infliximab and Biosimilar Market Facts & Figures by Country 3.6.1 Latin America Infliximab and Biosimilar Sales by Country 3.6.2 Latin America Infliximab and Biosimilar Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Infliximab and Biosimilar Market Facts & Figures by Country 3.7.1 Middle East and Africa Infliximab and Biosimilar Sales by Country 3.7.2 Middle East and Africa Infliximab and Biosimilar Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Infliximab and Biosimilar Historic Market Analysis by Type 4.1 Global Infliximab and Biosimilar Sales Market Share by Type (2016-2021) 4.2 Global Infliximab and Biosimilar Revenue Market Share by Type (2016-2021) 4.3 Global Infliximab and Biosimilar Price by Type (2016-2021) 5 Global Infliximab and Biosimilar Historic Market Analysis by Application 5.1 Global Infliximab and Biosimilar Sales Market Share by Application (2016-2021) 5.2 Global Infliximab and Biosimilar Revenue Market Share by Application (2016-2021) 5.3 Global Infliximab and Biosimilar Price by Application (2016-2021) 6 Key Companies Profiled 6.1 Janssen Biotech 6.1.1 Janssen Biotech Corporation Information 6.1.2 Janssen Biotech Description and Business Overview 6.1.3 Janssen Biotech Infliximab and Biosimilar Sales, Revenue and Gross Margin (2016-2021) 6.1.4 Janssen Biotech Infliximab and Biosimilar Product Portfolio 6.1.5 Janssen Biotech Recent Developments/Updates 6.2 Merck and Co. 6.2.1 Merck and Co. Corporation Information 6.2.2 Merck and Co. Description and Business Overview 6.2.3 Merck and Co. Infliximab and Biosimilar Sales, Revenue and Gross Margin (2016-2021) 6.2.4 Merck and Co. Infliximab and Biosimilar Product Portfolio 6.2.5 Merck and Co. Recent Developments/Updates 6.3 Pfizer 6.3.1 Pfizer Corporation Information 6.3.2 Pfizer Description and Business Overview 6.3.3 Pfizer Infliximab and Biosimilar Sales, Revenue and Gross Margin (2016-2021) 6.3.4 Pfizer Infliximab and Biosimilar Product Portfolio 6.3.5 Pfizer Recent Developments/Updates 7 Infliximab and Biosimilar Manufacturing Cost Analysis 7.1 Infliximab and Biosimilar Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Infliximab and Biosimilar 7.4 Infliximab and Biosimilar Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Infliximab and Biosimilar Distributors List 8.3 Infliximab and Biosimilar Customers 9 Infliximab and Biosimilar Market Dynamics 9.1 Infliximab and Biosimilar Industry Trends 9.2 Infliximab and Biosimilar Growth Drivers 9.3 Infliximab and Biosimilar Market Challenges 9.4 Infliximab and Biosimilar Market Restraints 10 Global Market Forecast 10.1 Infliximab and Biosimilar Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Infliximab and Biosimilar by Type (2022-2027) 10.1.2 Global Forecasted Revenue of Infliximab and Biosimilar by Type (2022-2027) 10.2 Infliximab and Biosimilar Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Infliximab and Biosimilar by Application (2022-2027) 10.2.2 Global Forecasted Revenue of Infliximab and Biosimilar by Application (2022-2027) 10.3 Infliximab and Biosimilar Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Infliximab and Biosimilar by Region (2022-2027) 10.3.2 Global Forecasted Revenue of Infliximab and Biosimilar by Region (2022-2027) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Infliximab and Biosimilar Sales (K Units) Growth Rate Comparison by Type (2021-2027) Table 2. Global Infliximab and Biosimilar Sales (K Units) Comparison by Application (2021-2027) Table 3. Global Infliximab and Biosimilar Market Size by Region (US$ Million) (2016 VS 2021 VS 2027) Table 4. Key Manufacturers Infliximab and Biosimilar Covered in This Study Table 5. Global Infliximab and Biosimilar Sales (K Units) of Key Manufacturers (2016-2021) Table 6. Global Infliximab and Biosimilar Sales Market Share by Manufacturers (2016-2021) Table 7. Global Infliximab and Biosimilar Revenue (US$ Million) by Manufacturers (2016-2021) Table 8. Global Infliximab and Biosimilar Revenue Share by Manufacturers (2016-2021) Table 9. Global Market Infliximab and Biosimilar Average Price (USD/Unit) of Key Manufacturers (2016-2021) Table 10. Manufacturers Infliximab and Biosimilar Manufacturing Sites and Area Served Table 11. Manufacturers Infliximab and Biosimilar Product Type Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Infliximab and Biosimilar by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Infliximab and Biosimilar as of 2020) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Infliximab and Biosimilar Sales by Region (2016-2021) & (K Units) Table 16. Global Infliximab and Biosimilar Sales Market Share by Region (2016-2021) Table 17. Global Infliximab and Biosimilar Revenue by Region (2016-2021) & (US$ Million) Table 18. North America Infliximab and Biosimilar Sales by Country (2016-2021) & (K Units) Table 19. North America Infliximab and Biosimilar Sales Market Share by Country (2016-2021) Table 20. North America Infliximab and Biosimilar Revenue by Country (2016-2021) & (US$ Million) Table 21. North America Infliximab and Biosimilar Revenue Market Share by Country (2016-2021) Table 22. Europe Infliximab and Biosimilar Sales by Country (2016-2021) & (K Units) Table 23. Europe Infliximab and Biosimilar Sales Market Share by Country (2016-2021) Table 24. Europe Infliximab and Biosimilar Revenue by Country (2016-2021) & (US$ Million) Table 25. Europe Infliximab and Biosimilar Revenue Market Share by Country (2016-2021) Table 26. Asia Pacific Infliximab and Biosimilar Sales by Region (2016-2021) & (K Units) Table 27. Asia Pacific Infliximab and Biosimilar Sales Market Share by Region (2016-2021) Table 28. Asia Pacific Infliximab and Biosimilar Revenue by Region (2016-2021) & (US$ Million) Table 29. Asia Pacific Infliximab and Biosimilar Revenue Market Share by Region (2016-2021) Table 30. Latin America Infliximab and Biosimilar Sales by Country (2016-2021) & (K Units) Table 31. Latin America Infliximab and Biosimilar Sales Market Share by Country (2016-2021) Table 32. Latin America Infliximab and Biosimilar Revenue by Country (2016-2021) & (US$ Million) Table 33. Latin America Infliximab and Biosimilar Revenue Market Share by Country (2016-2021) Table 34. Middle East and Africa Infliximab and Biosimilar Sales by Country (2016-2021) & (K Units) Table 35. Middle East and Africa Infliximab and Biosimilar Sales Market Share by Country (2016-2021) Table 36. Middle East and Africa Infliximab and Biosimilar Revenue by Country (2016-2021) & (US$ Million) Table 37. Middle East and Africa Infliximab and Biosimilar Revenue Market Share by Country (2016-2021) Table 38. Global Infliximab and Biosimilar Sales (K Units) by Type (2016-2021) Table 39. Global Infliximab and Biosimilar Sales Market Share by Type (2016-2021) Table 40. Global Infliximab and Biosimilar Revenue (Million US$) by Type (2016-2021) Table 41. Global Infliximab and Biosimilar Revenue Share by Type (2016-2021) Table 42. Global Infliximab and Biosimilar Price (USD/Unit) by Type (2016-2021) Table 43. Global Infliximab and Biosimilar Sales (K Units) by Application (2016-2021) Table 44. Global Infliximab and Biosimilar Sales Market Share by Application (2016-2021) Table 45. Global Infliximab and Biosimilar Revenue (Million US$) by Application (2016-2021) Table 46. Global Infliximab and Biosimilar Revenue Share by Application (2016-2021) Table 47. Global Infliximab and Biosimilar Price (USD/Unit) by Application (2016-2021) Table 48. Janssen Biotech Corporation Information Table 49. Janssen Biotech Description and Business Overview Table 50. Janssen Biotech Infliximab and Biosimilar Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 51. Janssen Biotech Infliximab and Biosimilar Product Table 52. Janssen Biotech Recent Developments/Updates Table 53. Merck and Co. Corporation Information Table 54. Merck and Co. Description and Business Overview Table 55. Merck and Co. Infliximab and Biosimilar Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 56. Merck and Co. Infliximab and Biosimilar Product Table 57. Merck and Co. Recent Developments/Updates Table 58. Pfizer Corporation Information Table 59. Pfizer Description and Business Overview Table 60. Pfizer Infliximab and Biosimilar Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 61. Pfizer Infliximab and Biosimilar Product Table 62. Pfizer Recent Developments/Updates Table 63. Production Base and Market Concentration Rate of Raw Material Table 64. Key Suppliers of Raw Materials Table 65. Infliximab and Biosimilar Distributors List Table 66. Infliximab and Biosimilar Customers List Table 67. Infliximab and Biosimilar Market Trends Table 68. Infliximab and Biosimilar Growth Drivers Table 69. Infliximab and Biosimilar Market Challenges Table 70. Infliximab and Biosimilar Market Restraints Table 71. Global Infliximab and Biosimilar Sales Forecast by Type (2022-2027) & (K Units) Table 72. Global Infliximab and Biosimilar Sales Market Share Forecast by Type (2022-2027) Table 73. Global Infliximab and Biosimilar Revenue Forecast by Type (2022-2027) & (US$ Million) Table 74. Global Infliximab and Biosimilar Revenue Market Share Forecast by Type (2022-2027) Table 75. Global Infliximab and Biosimilar Sales Forecast by Application (2022-2027) & (K Units) Table 76. Global Infliximab and Biosimilar Sales Market Share Forecast by Application (2022-2027) Table 77. Global Infliximab and Biosimilar Revenue Forecast by Application (2022-2027) & (US$ Million) Table 78. Global Infliximab and Biosimilar Revenue Market Share Forecast by Application (2022-2027) Table 79. Global Infliximab and Biosimilar Sales Forecast by Region (2022-2027) & (K Units) Table 80. Global Infliximab and Biosimilar Sales Market Share Forecast by Region (2022-2027) Table 81. Global Infliximab and Biosimilar Revenue Forecast by Region (2022-2027) & (US$ Million) Table 82. Global Infliximab and Biosimilar Revenue Market Share Forecast by Region (2022-2027) Table 83. Research Programs/Design for This Report Table 84. Key Data Information from Secondary Sources Table 85. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Infliximab and Biosimilar Figure 2. Global Infliximab and Biosimilar Market Share by Type in 2020 & 2027 Figure 3. Infliximab Product Picture Figure 4. Infliximab-dyyb Product Picture Figure 5. Infliximab-abda Product Picture Figure 6. Global Infliximab and Biosimilar Market Share by Application in 2020 & 2027 Figure 7. Crohn's Disease Figure 8. Pediatric Crohn's Disease Figure 9. Ulcerative Colitis Figure 10. Rheumatoid Arthritis Figure 11. Ankylosing Spondylitis Figure 12. Psoriatic Arthritis Figure 13. Plaque Psoriasis Figure 14. Global Infliximab and Biosimilar Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 15. Global Infliximab and Biosimilar Market Size 2016-2027 (US$ Million) Figure 16. Global Infliximab and Biosimilar Sales 2016-2027 (K Units) Figure 17. Global Infliximab and Biosimilar Market Size Market Share by Region: 2016 VS 20210 VS 2027 Figure 18. Infliximab and Biosimilar Sales Share by Manufacturers in 2020 Figure 19. Global Infliximab and Biosimilar Revenue Share by Manufacturers in 2020 Figure 20. The Global 5 and 10 Largest Infliximab and Biosimilar Players: Market Share by Revenue in 2020 Figure 21. Infliximab and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021 Figure 22. Global Infliximab and Biosimilar Sales Market Share by Region (2016-2021) Figure 23. Global Infliximab and Biosimilar Sales Market Share by Region in 2020 Figure 24. Global Infliximab and Biosimilar Revenue Market Share by Region (2016-2021) Figure 25. Global Infliximab and Biosimilar Revenue Market Share by Region in 2020 Figure 26. U.S. Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 27. Canada Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 28. Germany Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 29. France Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 30. U.K. Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 31. Italy Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 32. Russia Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 33. China Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 34. Japan Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 35. South Korea Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 36. India Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 37. Australia Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 38. Taiwan Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 39. Indonesia Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 40. Thailand Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 41. Malaysia Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 42. Philippines Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 43. Vietnam Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 44. Mexico Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 45. Brazil Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 46. Argentina Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 47. Turkey Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 48. Saudi Arabia Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 49. U.A.E Infliximab and Biosimilar Revenue Growth Rate (2016-2021) (US$ Million) Figure 50. Sales Market Share of Infliximab and Biosimilar by Type (2016-2021) Figure 51. Sales Market Share of Infliximab and Biosimilar by Application (2016-2021) Figure 52. Sales Market Share of Infliximab and Biosimilar by Application in 2020 Figure 53. Revenue Share of Infliximab and Biosimilar by Application (2016-2021) Figure 54. Revenue Share of Infliximab and Biosimilar by Application in 2020 Figure 55. Manufacturing Cost Structure of Infliximab and Biosimilar Figure 56. Manufacturing Process Analysis of Infliximab and Biosimilar Figure 57. Infliximab and Biosimilar Industrial Chain Analysis Figure 58. Channels of Distribution Figure 59. Distributors Profiles Figure 60. Bottom-up and Top-down Approaches for This Report Figure 61. Data Triangulation Figure 62. Key Executives Interviewed

Janssen Biotech Merck and Co. Pfizer